Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409612 | 1.00 | MKNK2 (0.71) | MKNK2MKNK1 | |
| SCHEMBL2406149 | 1.00 | MKNK2 (0.71) | MKNK2MKNK1 | |
| SCHEMBL2406775 | 0.95 | MKNK2 (0.65) | MKNK2MKNK1 | |
| SCHEMBL2406781 | 0.95 | MKNK2 (0.65) | MKNK2MKNK1 | |
| SCHEMBL12279646 | 0.95 | MKNK2 (0.65) | MKNK2MKNK1 | |
| SCHEMBL2408551 | 0.95 | MKNK2 (0.78) | MKNK2MKNK1 | |
| SCHEMBL15468240 | 0.93 | MKNK2 (0.71) | MKNK2MKNK1 | |
| SCHEMBL2404651 | 0.93 | MKNK2 (0.72) | MKNK2MKNK1 | |
| SCHEMBL12279133 | 0.93 | MKNK2 (0.72) | MKNK2MKNK1 | |
| SCHEMBL2404655 | 0.93 | MKNK2 (0.72) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539346-B1 | 4-[HETEROCYCLOALKYLOXY(HETERO)ARYLAMINO] THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-8648068-B2 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, TNK2, CMPK1 | MKNK2 18/4885MKNK1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.